DOCSLIB.ORG

View/Download Slides

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
View/Download Slides Uncomfortable rash and recurrent pancreatitis in 40 yo man Daniel Soffer MD FNLA University of Pennsylvania Division of Internal Medicine, Translational Medicine and Human Genetics FINANCIAL DISCLOSURE: Consultant Akcea Therapeutics, Kaneka (apheresis), Novartis Investigator Amgen Inc, Akcea Therapeutics, Novartis, Regeneron, RegenXBio, Astra-Zeneca UNLABELED/UNAPPROVED USES DISCLOSURE: none Outline • Brief case oBackground: severe hypertriglyceridemia oMaking the diagnosis oTreatment considerations oFuture direction Joe • 37 yo obese (BMI 50) nonsmoker; referred bc of severe hyperTG. • h/o pancreatitis x3 (1st at 35 yo) • t2dm (A1C 8-10%) • h/o gout, arthritis, OSA, fatty liver oNormal thyroid; no nephrotic syn oNo EtOH 3 Joe • Choline fenofibrate 135 mg Lipids 2011 daily (mg/dL) • Niacin ER 500 mg daily TC 592 • Omega-3-acid ethyl esters 1 TG 4565 gm twice daily HDL-C 34 • Rosuvastatin calcium 20 mg daily • Metformin 500 mg 2 times daily • Saxagliptin hcl 5 mg daily • Valsartan 160 mg daily 4 Joe’s pedigree Hyperlipidemia Joe Developed painful xanthomas • 40 yo; conditions unchanged • Deferring bariatric surgery (BMI 50) Lab Results Units 12/2013 12/2013 1/2014 CHOL 946 852 970 TRIG 6,922 6,100 8,860 CHOLHDL 13 8 10 mg/dL CREATININE 0.73 GLUCOSE 204 HEMOGLOBIN % A1C 10.0 6 Images shared with permission from patient Joe Lab Results TRIG Ref Rng & Units mg/dL 7/15/2014 >10,000 (H) 7/17/2014 7,719 (H) 7/21/2014 5,450 (H) 7/24/2014 5,758 (H) 7/24/2014 2,861 (H) 7/28/2014 6,016 (H) 8/1/2014 4723 8/4/2014 5,055 (H) 8/7/2014 5,682 (H) 8/11/2014 6,384 (H) 8/14/2014 5226 8/25/2014 5,729 (H) 8/28/2014 3,375 (H) 9/4/2014 9/8/2014 >10,000 (H) 9/15/2014 1,863 (H) 9/18/2014 2,909 (H) 9/19/2014 9/25/2014 1,879 (H) 9/29/2014 2,381 (H) 10/2/2014 2,775 (H) 10/6/2014 1390 7 Images shared with permission from patient Overall Prevalence of Hypertriglyceridemia 2014 National Lipid Association (NLA) by Age in NHANES (representative sample) Classification of TG Levels 1999-2008 Triglycerides (mg/dL) Demographic TG ≥150 mg/dL <150 Normal Overall (age 150–199 Borderline high 25.0% ≥20 y) 200–499 High Men 28.7% ≥500 Very high Women 21.5% U.S. Census Age 20 and above, July 1, 2010, was 226,113,653. Jacobson TA, Maki KC, Orringer CE, et al. J Clin Lipidol. Carroll MD et al. NCHS Data Brief, No 198. National Center for Health 8Statistics. 2015. 2015. 9(6) S1-S122.e1. doi:10.1016/j.jacl.2015.09.002 https://www.cdc.gov/nchs/products/databriefs/db198.htm Plasma TG concentrations and expected genetic variants associated from ~70 000 adults (>20 years of age) from the Copenhagen General Population Study. 1 mmol/L = 88.57 mg/dL 2 mmol/L = 177.14 9 Hegele RA et al. Lancet Diabetes & Endocrinology.2014;2(8):655-666 Very Severe Hypertriglyceridemia in a Large US County Health Care System (n ~70 000): Associated Conditions and Management very severe hyperTG % pts w/lipid profile 0.14% 103 of 71 495 TG > 2000 mg/dL (<0.1%) the rest 99.86% Maria Isabel Esparza MI, et al. Journal of the Endocrine Society, 2019. 3(8): 1595–1607, https://doi.org/10.1210/js.2019-00129 Hypertriglyceridemia: etiology Acquired/environmental (post- transcriptional) “Most cases of HTG are felt to be • Diet, EtOH polygenic, with strong influence by environmental factors.” • Meds • Metabolic conditions • Medical conditions Gary F. Lewis, Changting Xiao, Robert A. Hegele; Hypertriglyceridemia in the Genomic Era: A New Paradigm, Endocrine Reviews, Volume 36, Issue 1, 2 February 2015, Pages 131–147, https://doi.org/10.1210/er.2014-1062 Inherited syndromes • Monogenic (FCS, FDBL) • Polygenic (MCS, FCH, FHTG) 11 MCS multifactorial CM syndrome, FCH familial combined hyperlipidemia, FHTG familial hypertriglyceridemia, FDBL familial dysbetalipoproteinemia High TGs Acute ASCVD pancreatitis TG risk >440 vs <88 mg/dL (women>men) MI IHD MI Myocardial infarction IHD Ischemic heart disease ischemic stroke all cause mortality 0 5 10 15 20 (MEN) Copenhagen Heart Study (WOMEN) from WHI Freiberg JJ, Tybjaerg-Hansen A, Jensen JS, Nordestgaard BG. JAMA. 2008;300:2142–2152. doi: 10.1001/jama.2008.621 Bansal S, Buring JE, Rifai N, Mora S, Sacks FM, Ridker PM. JAMA. 2007;298:309–316. doi: 10.1001/jama.298.3.309. TG/TRL atherosclerosis direct, indirect, bystander B48 B FA A1 TRLr HDL Lipolysis Vascular lumen Endothelium Subendothelial B Macrophage space/GP matrix Remnant Foam cells Uptake ABCA1, SRB1 B Apolipoprotein B A1 ABCA1 ATP binding cassette A1 Cholesterol efflux SRB1 Scavenger receptor class B, type 1 HDL HDL High density lipoprotein A1 Apolipoprotein A1 Adapted from Watts GF et al. Nat Rev Cardiol. 2013;10(11):648-61. TRLr TG rich lipoprotein remnant High TG/CM, genetic association Acute pancreatitis Stroes E et al. Atherosclerosis Supplements 2017;23:1-7 400 361.4 350 High TRL/CMexposed to lipase in 300 pancreatic capillaries 250 200 150 Inflammatory FFAtrypsin pancreatitis OR acute 100 55.8 50 activation/pancreatic necrosis 15.8 0 moderate TG (5-9 mmol/L severe TG (>9 mmol/L LPLd; n=28 [442-797 mg/dL]), n=487 [>797 mg/dL]); n=354 LipaseFFA release from TRL/CM; moderate TG (5-9 mmol/L [442-797 mg/dL]), n=487 vicious cycle severe TG (>9 mmol/L [>797 mg/dL]); n=354 LPLd; n=28 15 TRL lifecycle: synthesis clearance/atherosclerosis HL VLDL LRP E TRL TRLr LDL CM LPL LPL ER Endoplasmic reticulum LMF1 Lipase maturation factor 1 SEL1L Sel1-Suppressor of Lin-12-Like 1-HRD1 ER-associated degradation HSPG Heparan sulfate proteoglycan GPIHBP1 glycophosphatidyl-inositol HDL binding protein 1 Young SG, Davies BS, Fong LG, et al. Curr Opin Lipidol. 2007;18(4):389-396. doi:10.1097/MOL.0b013e3281527914 Wu SA, Kersten S, Qi L. Trends Endocrinol Metab. 2020. 32(1):48-61. doi:10.1016/j.tem.2020.11.005 Apos Apolipoproteins Schematic representation (Venn diagram) of associated conditions for serum triglyceride levels ≥2000 mg/dL ... 103 of 71 495 patients who had lipid testing in 2016, had TG > 2000 mg/dL (<0.1%) Maria Isabel Esparza MI, et al. Journal of the Endocrine Society, 2019. 3(8): 1595–1607, https://doi.org/10.1210/js.2019-00129 Genetic testing in dyslipidemia: a scientific statement from the NLA Genetic testing in severe hypertriglyceridemia (SHTG) is III C-EO generally not indicated because most SHTG is polygenic or multifactorial. Genetic testing in severe hypertriglyceridemia may be IIb C-EO reasonable if a monogenic disorder is suspected clinically such as familial chylomicronemia syndrome (eg, young age, failure to thrive, relapsing pancreatitis, and absence of secondary causes). Brown, E. E et al. Journal of Clinical Lipidology, 2020.14(4), 398–413. https://doi.org/10.1016/j.jacl.2020.04.011 Is it FCS? Images used with patient permission Moulin P et al. Atherosclerosis, 2018. 275:265-272. ISSN 0021-9150. https://doi.org/10.1016/j.atherosclerosis.2018.06.814. Joe •Pathogenic mutations in LPL, APOC2, APOA5, LMF1, GP1HBP1, GCKR, CREBH; APOE2/3 •Polygenic TG risk score 21/28 21 Images shared with permission from patient Should TGs be treated? Nordestgaard BG. Circ Res. 2016 Feb 19;118(4):547-63. doi: 10.1161/CIRCRESAHA.115.306249. PMID: 26892957. Severe Hypertriglyceridemia Recommendations for Hypertriglyceridemia COR LOE Recommendations In adults 40 to 75 years of age with severe hypertriglyceridemia (fasting triglycerides ≥500 mg/dL [≥5.6 mmol/L]) or higher, IIa B-R and ASCVD risk of 7.5% it is reasonable to address reversible causes of high triglyceride and to initiate statin therapy. In adults with severe hypertriglyceridemia (fasting triglycerides ≥500 mg/dL [≥5.7 mmol/L]), and especially fasting triglycerides ≥1000 mg/dL (11.3 mmol/L)), it is reasonable to identify and address other causes of hypertriglyceridemia), and if triglycerides are persistently elevated or increasing, IIa B-NR to further reduce triglycerides by implementation of a very low-fat diet, avoidance of refined carbohydrates and alcohol, consumption of omega-3 fatty acids, and, if necessary to prevent acute pancreatitis, fibrate therapy. 23 Grundy et al. Circulation 2018. VERY LOW-FAT DIET The main focus for CM clearing is very low-fat meal plan with no more than 20-30 g of fat per day. https://www.lipid.org/sites/default/files/when_your_tgs_are_over_1000_mgdl.pdf Joe’s future Complications from… • Plasma exchange • Bariatric surgery • HyperCM/TG o Recurrent AP o Recurrent xanthomas o ASCVD risk ASO-APOC3 • obesity, diabetes and OSA Anti-AngPTL3 (ASO, mAb) o Arthritis o Neuropathy o CKD o Optho o ED o Cor pulmonale o Liver dz o Etc… Severe hypertriglyceridemia • …the consequence of combined impact from genes and environment • …associated with ASCVD and acute pancreatitis • Tx o ASCVD risk: environment and lifestyle modification/statins o AP risk: environment and lifestyle modification/TG-lowering Rx • Genetic testing may inform expectations and novel therapy 26 Uncomfortable rash and recurrent pancreatitis in 40 yo man Daniel Soffer MD FNLA University of Pennsylvania Division of Internal Medicine, Translational Medicine and Human Genetics FINANCIAL DISCLOSURE: Consultant Akcea Therapeutics, Kaneka (apheresis), Novartis Investigator Amgen Inc, Akcea Therapeutics, Novartis, Regeneron, RegenXBio, Astra-Zeneca UNLABELED/UNAPPROVED USES DISCLOSURE: none Severe Hypertriglyceridemia – Pharmacotherapy Allison Hester, PharmD, BCACP Disclosures Allison Hester, PharmD, BCACP has no financial relationships to disclose in relation to this presentation. Outline Medications TG Current Pipeline that treatment medications medications contribute goals to treat HTG for HTG to HTG HTG: hypertriglyceridemia; TG: triglyceride Medications that can contribute to hypertriglyceridemia Beta-blockers Tamoxifen, Thiazides Corticosteroids (non-selelctive) raloxifene Estrogens Retinoic acid, Immunosuppressants Protease inhibitors (oral, not topical) isotretinoin (i.e., sirolimus) Antipsychotics L-Asparaginase Bile acid resins Phenothiazines (second generation) Curr Cardiol Rev.
Load more

Recommended publications
  • Classification Decisions Taken by the Harmonized System Committee from the 47Th to 60Th Sessions (2011
    CLASSIFICATION DECISIONS TAKEN BY THE HARMONIZED SYSTEM COMMITTEE FROM THE 47TH TO 60TH SESSIONS (2011 - 2018) WORLD CUSTOMS ORGANIZATION Rue du Marché 30 B-1210 Brussels Belgium November 2011 Copyright © 2011 World Customs Organization. All rights reserved. Requests and inquiries concerning translation, reproduction and adaptation rights should be addressed to [email protected]. D/2011/0448/25 The following list contains the classification decisions (other than those subject to a reservation) taken by the Harmonized System Committee ( 47th Session – March 2011) on specific products, together with their related Harmonized System code numbers and, in certain cases, the classification rationale. Advice Parties seeking to import or export merchandise covered by a decision are advised to verify the implementation of the decision by the importing or exporting country, as the case may be. HS codes Classification No Product description Classification considered rationale 1. Preparation, in the form of a powder, consisting of 92 % sugar, 6 % 2106.90 GRIs 1 and 6 black currant powder, anticaking agent, citric acid and black currant flavouring, put up for retail sale in 32-gram sachets, intended to be consumed as a beverage after mixing with hot water. 2. Vanutide cridificar (INN List 100). 3002.20 3. Certain INN products. Chapters 28, 29 (See “INN List 101” at the end of this publication.) and 30 4. Certain INN products. Chapters 13, 29 (See “INN List 102” at the end of this publication.) and 30 5. Certain INN products. Chapters 28, 29, (See “INN List 103” at the end of this publication.) 30, 35 and 39 6. Re-classification of INN products.
    [Show full text]
  • N-Acetyl Galactosamine-Conjugated Antisense Drug to APOC3 Mrna, Triglycerides and Atherogenic Lipoprotein Levels
    European Heart Journal (2019) 40, 2785–2796 CLINICAL RESEARCH doi:10.1093/eurheartj/ehz209 Lipids N-acetyl galactosamine-conjugated antisense drug to APOC3 mRNA, triglycerides and atherogenic lipoprotein levels Veronica J. Alexander1, Shuting Xia1, Eunju Hurh2, Steven G. Hughes1, Louis O’Dea2, Richard S. Geary1, Joseph L. Witztum3, and Sotirios Tsimikas1,4* 1Ionis Pharmaceuticals, Inc., 2855 Gazelle Ct, Carlsbad, CA 92010, USA; 2Akcea Therapeutics, 22 Boston Wharf Road, 9th Floor, Boston, MA 02210, USA; 3Division of Endocrinology and Metabolism, University of California San Diego, 9500 Gilman Drive, La Jolla, CA 92093-0682, USA; and 4Division of Cardiovascular Medicine, Sulpizio Cardiovascular Center, Vascular Medicine Program, University of California San Diego, 9500 Gilman Drive, La Jolla, CA 92093-0682, USA Received 15 January 2019; revised 8 March 2019; editorial decision 25 March 2019; accepted 4 April 2019; online publish-ahead-of-print 24 April 2019 See page 2797 for the editorial comment on this article (doi: 10.1093/eurheartj/ehz321) Aims Elevated apolipoprotein C-III (apoC-III) levels are associated with hypertriglyceridaemia and coronary heart disease. AKCEA-APOCIII-LRx is an N-acetyl galactosamine-conjugated antisense oligonucleotide targeted to the liver that selectively inhibits apoC-III protein synthesis. ................................................................................................................................................................................................... Methods The safety, tolerability, and efficacy of AKCEA-APOCIII-LRx was assessed in a double-blind, placebo-controlled, and results dose-escalation Phase 1/2a study in healthy volunteers (ages 18–65) with triglyceride levels >_90 or >_200 mg/dL. Single-dose cohorts were treated with 10, 30, 60, 90, and 120 mg subcutaneously (sc) and multiple-dose cohorts were treated with 15 and 30 mg weekly sc for 6 weeks or 60 mg every 4 weeks sc for 3 months.
    [Show full text]
  • Pemafibrate, a Novel Selective Peroxisome Proliferator-Activated
    www.nature.com/scientificreports OPEN Pemafibrate, a novel selective peroxisome proliferator-activated receptor alpha modulator, Received: 25 July 2016 Accepted: 11 January 2017 improves the pathogenesis in Published: 14 February 2017 a rodent model of nonalcoholic steatohepatitis Yasushi Honda1, Takaomi Kessoku1, Yuji Ogawa1, Wataru Tomeno1, Kento Imajo1, Koji Fujita1, Masato Yoneda1, Toshiaki Takizawa2, Satoru Saito1, Yoji Nagashima3 & Atsushi Nakajima1 The efficacy of peroxisome proliferator-activated receptorα -agonists (e.g., fibrates) against nonalcoholic fatty liver disease (NAFLD)/nonalcoholic steatohepatitis (NASH) in humans is not known. Pemafibrate is a novel selective peroxisome proliferator-activated receptorα modulator that can maximize the beneficial effects and minimize the adverse effects of fibrates used currently. In a phase-2 study, pemafibrate was shown to improve liver dysfunction in patients with dyslipidaemia. In the present study, we first investigated the effect of pemafibrate on rodent models of NASH. Pemafibrate efficacy was assessed in a diet-induced rodent model of NASH compared with fenofibrate. Pemafibrate and fenofibrate improved obesity, dyslipidaemia, liver dysfunction, and the pathological condition of NASH. Pemafibrate improved insulin resistance and increased energy expenditure significantly. To investigate the effects of pemafibrate, we analysed the gene expressions and protein levels involved in lipid metabolism. We also analysed uncoupling protein 3 (UCP3) expression. Pemafibrate stimulated lipid turnover and upregulated UCP3 expression in the liver. Levels of acyl-CoA oxidase 1 and UCP3 protein were increased by pemafibrate significantly. Pemafibrate can improve the pathogenesis of NASH by modulation of lipid turnover and energy metabolism in the liver. Pemafibrate is a promising therapeutic agent for NAFLD/NASH. The incidence of nonalcoholic fatty liver disease (NAFLD) is increasing worldwide.
    [Show full text]
  • A61p1/16 (2006.01) A61p3/00 (2006.01) Km, Ml, Mr, Ne, Sn, Td, Tg)
    ( (51) International Patent Classification: TR), OAPI (BF, BJ, CF, CG, Cl, CM, GA, GN, GQ, GW, A61P1/16 (2006.01) A61P3/00 (2006.01) KM, ML, MR, NE, SN, TD, TG). A61K 31/192 (2006.01) C07C 321/28 (2006.01) Declarations under Rule 4.17: (21) International Application Number: — as to the applicant's entitlement to claim the priority of the PCT/IB2020/000808 earlier application (Rule 4.17(iii)) (22) International Filing Date: Published: 25 September 2020 (25.09.2020) — with international search report (Art. 21(3)) (25) Filing Language: English — before the expiration of the time limit for amending the claims and to be republished in the event of receipt of (26) Publication Language: English amendments (Rule 48.2(h)) (30) Priority Data: 62/906,288 26 September 2019 (26.09.2019) US (71) Applicant: ABIONYX PHARMA SA [FR/FR] ; 33-43 Av¬ enue Georges Pompidou, Batiment D, 31130 Bahna (FR). (72) Inventor: DASSEUX, Jean-Louis, Henri; 7 Allees Charles Malpel, Bat. B, 31300 Toulouse (FR). (74) Agent: HOFFMANN EITLE PATENT- UND RECHTSANWALTE PARTMBB, ASSOCIATION NO. 151; Arabellastrasse 30, 81925 Munich (DE). (81) Designated States (unless otherwise indicated, for every kind of national protection available) : AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.
    [Show full text]
  • Statin-Induced Myopathy: Translational Studies from Preclinical to Clinical Evidence
    International Journal of Molecular Sciences Review Statin-Induced Myopathy: Translational Studies from Preclinical to Clinical Evidence Giulia Maria Camerino 1, Nancy Tarantino 1 , Ileana Canfora 1 , Michela De Bellis 1, Olimpia Musumeci 2 and Sabata Pierno 1,* 1 Section of Pharmacology, Department of Pharmacy and Drug Sciences, University of Bari “Aldo Moro”, 70125 Bari, Italy; [email protected] (G.M.C.); [email protected] (N.T.); [email protected] (I.C.); [email protected] (M.D.B.) 2 Unit of Neurology and Neuromuscular Disorders, Department of Clinical and Experimental Medicine, University of Messina, 98122 Messina, Italy; [email protected] * Correspondence: [email protected] Abstract: Statins are the most prescribed and effective drugs to treat cardiovascular diseases (CVD). Nevertheless, these drugs can be responsible for skeletal muscle toxicity which leads to reduced compliance. The discontinuation of therapy increases the incidence of CVD. Thus, it is essential to assess the risk. In fact, many studies have been performed at preclinical and clinical level to investigate pathophysiological mechanisms and clinical implications of statin myotoxicity. Conse- quently, new toxicological aspects and new biomarkers have arisen. Indeed, these drugs may affect gene transcription and ion transport and contribute to muscle function impairment. Identifying a marker of toxicity is important to prevent or to cure statin induced myopathy while assuring the right therapy for hypercholesterolemia and counteracting CVD. In this review we focused on the mechanisms of muscle damage discovered in preclinical and clinical studies and highlighted the Citation: Camerino, G.M.; Tarantino, pathological situations in which statin therapy should be avoided.
    [Show full text]
  • Effects of Pemafibrate on Glucose Metabolism Markers and Liver
    Yokote et al. Cardiovasc Diabetol (2021) 20:96 https://doi.org/10.1186/s12933-021-01291-w Cardiovascular Diabetology ORIGINAL INVESTIGATION Open Access Efects of pemafbrate on glucose metabolism markers and liver function tests in patients with hypertriglyceridemia: a pooled analysis of six phase 2 and phase 3 randomized double‐blind placebo‐controlled clinical trials Koutaro Yokote1,2*, Shizuya Yamashita3, Hidenori Arai4, Eiichi Araki5, Mitsunori Matsushita6, Toshiaki Nojima7, Hideki Suganami7 and Shun Ishibashi8 Abstract Background: Increased risk of cardiovascular events is associated not only with dyslipidemias, but also with abnor- malities in glucose metabolism and liver function. This study uses pooled analysis to explore the in-depth efects of pemafbrate, a selective peroxisome proliferator-activated receptor α modulator (SPPARMα) already known to decrease elevated triglycerides, on glucose metabolism and liver function in patients with hypertriglyceridemia. Methods: We performed a post-hoc analysis of six phase 2 and phase 3 Japanese randomized double-blind placebo- controlled trials that examined the efects of daily pemafbrate 0.1 mg, 0.2 mg, and 0.4 mg on glucose metabolism markers and liver function tests (LFTs). Primary endpoints were changes in glucose metabolism markers and LFTs from baseline after 12 weeks of pemafbrate treatment. All adverse events and adverse drug reactions were recorded as safety endpoints. Results: The study population was 1253 patients randomized to placebo (n 298) or pemafbrate 0.1 mg/day (n 127), 0.2 mg/day (n 584), or 0.4 mg/day (n 244). Participant mean age= was 54.3 years, 65.4 % had BMI 25 kg/ m2=, 35.8 % had type 2 diabetes,= and 42.6 % had fatty= liver.
    [Show full text]
  • Volanesorsen Fdaadvisory Committee Meeting Briefing Document
    VOLANESORSEN FDA ADVISORY COMMITTEE MEETING BRIEFING DOCUMENT ENDOCRINE AND METABOLIC DRUGS ADVISORY COMMITTEE MEETING DATE: 10 MAY 2018 ADVISORY COMMITTEE BRIEFING MATERIALS: AVAILABLE FOR PUBLIC RELEASE Volanesorsen (ISIS 304801) Akcea Therapeutics Endocrine and Metabolic Drugs Advisory Committee Briefing Document 10 May 2018 Meeting TABLE OF CONTENTS TABLE OF CONTENTS .................................................................................................................2 TABLE OF TABLES ......................................................................................................................6 TABLE OF FIGURES .....................................................................................................................9 LIST OF ABBREVIATIONS ........................................................................................................10 1. EXECUTIVE SUMMARY ........................................................................................11 1.1 Familial Chylomicronemia Syndrome ........................................................................12 1.1.1 Overview of the Disease and Impact of Elevated Triglyceride Levels ......................12 1.1.2 Current Treatment Options .........................................................................................14 1.2 Volanesorsen Clinical Development Program ............................................................15 1.3 Efficacy and Safety of Volanesorsen ..........................................................................15
    [Show full text]
  • News from European Society of Cardiology Aug31-Sept4
    The future of lipid-lowering drugs Vasculaire geneeskunde ‘From bench to bedside’ 11 september 2020 Hotel Theater Figi, Zeist Jan Albert Kuivenhoven Department of Pediatrics, Section Molecular Genetics University Medical Center Groningen, the Netherlands A current plethora of lipid-lowering drugs...... Registered ACL Five evidence-based drugs HMGCR to reduce LDLc* Treating homozygous familial hypercholesterolemia ∗ INCLIRISAN Treating rare monogenic disorders - lysosomal adic lipase deficiency - familial LCAT deficiency - lipoprotein lipase deficiency - familial chylomicronemia syndrome ∗ Under development NPC1L1 ABE Treating homozygous familial June, 2020 hypercholesterolemia Adapted from HegeleRA, CircRes 2019 ∗ Increasing cellular chol.efflux Phase II & III clinical trials to reduce high Lp(a), Tg, LDLc ∗ * Validated with Mendelian Randomization studies * Bempedoic acid/Ezetimibe - NDA filed Febr 2019 Lipid-lowering drugs • To reduce - LDL cholesterol - reduce atherosclerotic cardiovascular disease (ASCVD) - Triglycerides - ASCVD - severe hypertriglyceridemia - patients witn insulin resistance - Lipoprotein(a) - ASCVD • To treat rare monogenic disorders of lipid metabolism • To modulate steps in the reverse cholesterol pathway to reduce atherosclerosis Managing very severe hypercholesterolemia Extracorporeal removal of lipoproteins Nonspecific plasma exchange / plasmapheresis / specific targeted approaches to remove LDL/Lp(a). No randomized ASCVD outcome trials Block hepatic production of VLDL (precursor of LDL) Mipomersen – antisense
    [Show full text]
  • Efficacy and Safety of Pemafibrate Administration in Patients With
    Ida et al. Cardiovasc Diabetol (2019) 18:38 https://doi.org/10.1186/s12933-019-0845-x Cardiovascular Diabetology ORIGINAL INVESTIGATION Open Access Efcacy and safety of pemafbrate administration in patients with dyslipidemia: a systematic review and meta-analysis Satoshi Ida*, Ryutaro Kaneko and Kazuya Murata Abstract Background: Using a meta-analysis of randomized controlled trials (RCTs), this study aimed to investigate the ef- cacy and safety of pemafbrate, a novel selective peroxisome proliferator-activated receptor α modulator, in patients with dyslipidemia. Methods: A search was performed using the MEDLINE, Cochrane Controlled Trials Registry, and ClinicalTrials.gov databases. We decided to employ RCTs to evaluate the efects of pemafbrate on lipid and glucose metabolism- related parameters in patients with dyslipidemia. For statistical analysis, standardized mean diference (SMD) or odds ratio (OR) and 95% confdence intervals (CIs) were calculated using the random efect model. Results: Our search yielded seven RCTs (with a total of 1623 patients) that satisfed the eligibility criteria of this study; hence, those studies were incorporated into this meta-analysis. The triglyceride concentration signifcantly decreased in the pemafbrate group (SMD, 1.38; 95% CI, 1.63 to 1.12; P < 0.001) than in the placebo group, with a reduc- tion efect similar to that exhibited− by fenofbrate.− Compared− with the placebo group, the pemafbrate group also showed improvements in high-density and non-high-density lipoprotein cholesterol levels as well as in homeostasis model assessment for insulin resistance. Furthermore, the pemafbrate group showed a signifcant decrease in hepa- tobiliary enzyme activity compared with the placebo and fenofbrate groups; and, total adverse events (AEs) were signifcantly lower in the pemafbrate group than in the fenofbrate group (OR, 0.60; 95% CI, 0.49–0.73; P < 0.001).
    [Show full text]
  • Anatomical Classification Guidelines V2021 EPHMRA ANATOMICAL CLASSIFICATION GUIDELINES 2021
    EPHMRA ANATOMICAL CLASSIFICATION GUIDELINES 2021 Anatomical Classification Guidelines V2021 "The Anatomical Classification of Pharmaceutical Products has been developed and maintained by the European Pharmaceutical Marketing Research Association (EphMRA) and is therefore the intellectual property of this Association. EphMRA's Classification Committee prepares the guidelines for this classification system and takes care for new entries, changes and improvements in consultation with the product's manufacturer. The contents of the Anatomical Classification of Pharmaceutical Products remain the copyright to EphMRA. Permission for use need not be sought and no fee is required. We would appreciate, however, the acknowledgement of EphMRA Copyright in publications etc. Users of this classification system should keep in mind that Pharmaceutical markets can be segmented according to numerous criteria." © EphMRA 2021 Anatomical Classification Guidelines V2021 CONTENTS PAGE INTRODUCTION A ALIMENTARY TRACT AND METABOLISM 1 B BLOOD AND BLOOD FORMING ORGANS 28 C CARDIOVASCULAR SYSTEM 36 D DERMATOLOGICALS 51 G GENITO-URINARY SYSTEM AND SEX HORMONES 58 H SYSTEMIC HORMONAL PREPARATIONS (EXCLUDING SEX HORMONES) 68 J GENERAL ANTI-INFECTIVES SYSTEMIC 72 K HOSPITAL SOLUTIONS 88 L ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS 96 M MUSCULO-SKELETAL SYSTEM 106 N NERVOUS SYSTEM 111 P PARASITOLOGY 122 R RESPIRATORY SYSTEM 124 S SENSORY ORGANS 136 T DIAGNOSTIC AGENTS 143 V VARIOUS 145 Anatomical Classification Guidelines V2021 INTRODUCTION The Anatomical Classification was initiated in 1971 by EphMRA. It has been developed jointly by Intellus/PBIRG and EphMRA. It is a subjective method of grouping certain pharmaceutical products and does not represent any particular market, as would be the case with any other classification system.
    [Show full text]
  • Pemafibrate (K-877), a Novel Selective Peroxisome Proliferator-Activated
    Fruchart Cardiovasc Diabetol (2017) 16:124 DOI 10.1186/s12933-017-0602-y Cardiovascular Diabetology REVIEW Open Access Pemafbrate (K‑877), a novel selective peroxisome proliferator‑activated receptor alpha modulator for management of atherogenic dyslipidaemia Jean‑Charles Fruchart* Abstract Despite best evidence-based treatment including statins, residual cardiovascular risk poses a major challenge for clini‑ cians in the twenty frst century. Atherogenic dyslipidaemia, in particular elevated triglycerides, a marker for increased triglyceride-rich lipoproteins and their remnants, is an important contributor to lipid-related residual risk, especially in insulin resistant conditions such as type 2 diabetes mellitus. Current therapeutic options include peroxisome proliferator-activated receptor alpha (PPARα) agonists, (fbrates), but these have low potency and limited selectivity for PPARα. Modulating the unique receptor–cofactor binding profle to identify the most potent molecules that induce PPARα-mediated benefcial efects, while at the same time avoiding unwanted side efects, ofers a new therapeutic approach and provides the rationale for development of pemafbrate (K-877, Parmodia™), a novel selective PPARα modulator (SPPARMα). In clinical trials, pemafbrate either as monotherapy or as add-on to statin therapy was efec‑ tive in managing atherogenic dyslipidaemia, with marked reduction of triglycerides, remnant cholesterol and apoli‑ poprotein CIII. Pemafbrate also increased serum fbroblast growth factor 21, implicated in metabolic homeostasis. There were no clinically meaningful adverse efects on hepatic or renal function, including no relevant serum creati‑ nine elevation. A major outcomes study, PROMINENT, will provide defnitive evaluation of the role of pemafbrate for management of residual cardiovascular risk in type 2 diabetes patients with atherogenic dyslipidaemia despite statin therapy.
    [Show full text]
  • Review J Atheroscler Thromb, 2019; 26: 389-402
    The official journal of the Japan Atherosclerosis Society and the Asian Pacific Society of Atherosclerosis and Vascular Diseases Review J Atheroscler Thromb, 2019; 26: 389-402. http://doi.org/10.5551/jat.48918 Clinical Applications of a Novel Selective PPARα Modulator, Pemafibrate, in Dyslipidemia and Metabolic Diseases Shizuya Yamashita1, 2, 3, Daisaku Masuda1 and Yuji Matsuzawa4 1Department of Cardiology, Rinku General Medical Center, Osaka, Japan 2Department of Community Medicine, Osaka University Graduate School of Medicine, Osaka, Japan 3Department of Cardiovascular Medicine, Osaka University Graduate School of Medicine, Osaka, Japan 4Sumitomo Hospital, Osaka, Japan Fasting and postprandial hypertriglyceridemia is a risk factor for atherosclerotic cardiovascular diseases (ASCVD). Fibrates have been used to treat dyslipidemia, particularly hypertriglyceridemia, and low HDL-choles- terol (HDL-C). However, conventional fibrates have low selectivity for peroxisome proliferator-activated receptor (PPAR)α. Fibrates’ clinical use causes side effects such as worsening liver function and elevating the creatinine level. Large-scale clinical trials of fibrates have shown negative results for prevention of ASCVD. To overcome these issues, the concept of the selective PPARα modulator (SPPARMα), with a superior balance of efficacy and safety, has been proposed. A SPPARMα, pemafibrate (K-877), was synthesized by Kowa Company, Ltd. for bet- ter efficacy and safety. Clinical trials conducted in Japan confirmed the superior effects of pemafibrate on triglyc- eride reduction and HDL-C elevation. Conventional fibrates showed elevated liver function test values and worsened kidney function test values, while pemafibrate demonstrated improved liver function test values and was less likely to increase serum creati- nine or decrease the estimated glomerular filtration rate.
    [Show full text]